Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

US launch of new microbiome products generates plenty of interest, says Optibiotix

The event was attended by 16,500 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries
picture of gut
Microbiome is attracting huge interest from food and pharma groups

OptiBiotix Health PLC (LON:OPTI) has launched its SlimBiome and LP products in the US at the Supply Side West trade show.

Both products recently received FDA registration and the presentation at Supply Side West was the first in a number of steps to attract food, beverage, consumer healthcare and pharmaceutical partners for distribution and sale into the US market.

READ: Optibiotix Health lines up the targets for its “Precision microbiome engineering”

Cholesterol reducer LP was co-exhibited with Sacco, one of the largest suppliers of probiotic ingredients, while appetite suppressant SlimBiome was co-exhibited with specialty ingredients manufacturer, Cereal Ingredients. 

The event was attended by 16,500 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries with high interest from around the world, said the company.

Additionally, Optibiotix said that Sacco has appointed Dr Lucio Lepera as product manager for LP’s entry into the US probiotic market and extend it into the dairy market.

READ: OptiBiotix 'gaining real commercial traction' - CEO Stephen O'Hara

Cereal Ingredients, meanwhile, has incorporated SlimBiome into its range of cereal-based particulates and speciality ingredients that includes bakery products, breakfast cereals, crackers, toppings, products that extend it into the nutraceutical, health and wellbeing industry sectors. 

Stephen O'Hara, OptiBiotix’s chief executive, said in a statement: "We are extremely pleased with the very high level of interest from both national and multinational companies interested in our products and the opportunity to meet with senior US and Asian decision makers at Supply Side West. 

He added looking for partners was a low risk, low cost approach to accessing multiple consumer healthcare and pharmaceutical markets around the world with multiple products.

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

man at a micrscope
September 29 2017
The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
1511808112_surgeon.jpg
November 27 2017
In a letter to stakeholders, George Adams, the president and chief executive, highlighted that the device would "reduce the cost of its equipment significantly"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use